. 2021 May 28;12:582447. doi: 10.3389/fphar.2021.582447

TABLE 3.

Subgroup and meta-regression analysis.

Subgroups	Objective response rate (ORR)			Disease control rate (DCR)			Neutropenia			Gastrointestinal toxicity
Subgroups	OR (95% CI)	UM	MM	OR (95% CI)	UM	MM	OR (95% CI)	UM	MM	OR (95% CI)	UM	MM
Table 3A.Subgroups analysis according to KPS score (Supplementary Figures S35–S42)
KPS score (≥60)	1.87 [1.58, 2.22]	0.22	0.27	2.31 [1.84, 2.89]	0.57	0.47	0.42 [0.33, 0.54]	0.82	0.90	0.41 [0.33, 0.50]	0.32	0.64
KPS score (≥70)	1.40 [1.03, 1.90]			2.01 [1.36, 2.98]			0.33 [0.20, 0.54]			0.45 [0.31, 0.66]
KPS score (others)	1.94 [1.61, 2.33]			2.39 [1.87, 3.06]			0.43 [0.33, 0.55]			0.50 [0.40, 0.62]
Table 3B.Subgroups analysis according to AST (Supplementary Figures S35–S50)
AST (≥3m)	1.81 [1.56, 2.09]	0.28	0.99	2.20 [1.82, 2.66]	0.72	0.98	0.42 [0.34, 0.53]	0.78	0.90	0.47 [0.39, 0.56]	0.32	0.42
AST (≥5m)	1.98 [1.31, 3.00]			2.90 [1.69, 4.99]			0.40 [0.26, 0.61]			0.26 [0.15, 0.46]
AST (unclear)	1.80 [1.45, 2.24]			2.35 [1.74, 3.18]			0.40 [0.29, 0.55]			0.46 [0.36, 0.59]
Table 3C. Subgroups analysis via treatment process (Supplementary Figures S51–S58)
Primary treatment (PT)	1.46 [1.10, 1.94]	0.08	0.06	2.04 [1.41, 2.94]	0.27	0.20	0.46 [0.28, 0.76]	0.42	0.52	0.54 [0.36, 0.82]	0.81	0.41
Retreatment (RT)	2.88 [1.03, 8.07]			2.13 [0.62, 7.29]			1.00 [0.37, 2.71]			0.59 [0.22, 1.62]
PT and RT	1.08 [0.62, 1.89]			1.43 [0.65, 3.14]			0.29 [0.13, 0.63]			0.32 [0.16, 0.65]
Unclear	1.95 [1.71, 2.23]			2.41 [2.02, 2.87]			0.40 [0.33, 0.48]			0.44 [0.37, 0.51]
Table 3D. Subgroups analysis via age (Supplementary Figures S59–S66)
Age (≥60)	1.85 [1.36, 2.51]	0.91	0.88	2.22 [1.49, 3.30]	0.86	0.56	0.25 [0.15, 0.42]	0.04	0.09	0.46 [0.31, 0.69]	0.80	0.99
Age (others)	1.81 [1.60, 2.06]			2.30 [1.95, 2.72]			0.44 [0.37, 0.53]			0.44 [0.38, 0.52]
Table 3E. Subgroups analysis according to dosage (Supplementary Figures S67–S74)
50–60 ml	1.72 [1.49, 2.00]	0.75	0.88	2.21 [1.82, 2.68]	0.35	0.21	0.45 [0.37, 0.56]	0.32	0.58	0.47 [0.39, 0.56]	0.09	0.21
70–80 ml	1.85 [1.28, 2.68]			2.80 [1.73, 4.52]			0.24 [0.12, 0.48]			0.39 [0.25, 0.62]
90–100 ml	1.89 [1.35, 2.64]			2.55 [1.57, 4.14]			0.34 [0.21, 0.53]			0.30 [0.19, 0.48]
Others	2.16 [1.61, 2.89]			2.18 [1.48, 3.21]			0.41 [0.27, 0.63]			0.48 [0.35, 0.67]
Table 3F. Subgroups analysis according to time per cycle (Supplementary Figures S75–S82)
7–10days	1.75 [1.43, 2.13]	0.18	0.18	2.19 [1.70, 2.82]	0.48	0.53	0.35 [0.27, 0.46]	0.32	0.61	0.44 [0.35, 0.57]	0.97	0.41
14–15days	1.62 [1.35, 1.94]			1.87 [1.46, 2.38]			0.40 [0.31, 0.53]			0.45 [0.37, 0.55]
21–28days	2.48 [1.90, 3.25]			3.59 [2.46, 5.24]			0.62 [0.39, 1.00]			0.42 [0.29, 0.63]
Others	1.92 [1.13, 3.28]			3.23 [1.64, 6.37]			0.56 [0.28, 1.14]			No
Table 3G. Subgroups analysis according to treatment cycle (Supplementary Figures S83–S90)
One cycle	2.22 [1.44, 3.43]	0.70	0.40	2.54 [1.46, 4.41]	1.00	0.74	0.37 [0.21, 0.63]	0.35	0.78	0.41 [0.26, 0.66]	0.21	0.08
Two cycles	1.65 [1.40, 1.94]			2.08 [1.67, 2.58]			0.35 [0.27, 0.45]			0.46 [0.37, 0.57]
Three cycles	1.75 [1.24, 2.47]			2.48 [1.55, 3.96]			0.61 [0.41, 0.90]			0.45 [0.31, 0.65]
Four cycles	2.32 [1.68, 3.22]			2.59 [1.69, 3.95]			0.40 [0.27, 0.61]			0.35 [0.24, 0.51]
Others	1.91 [1.44, 2.52]			2.53 [1.75, 3.64]			0.45 [0.28, 0.70]			0.51 [0.37, 0.72]
Table 3H. Subgroups analysis according to DDP dosage (Supplementary Figures S91–S98)
20–30 mg/m²	1.83 [1.58, 2.12]	0.77	0.34	2.26 [1.87, 2.72]	0.98	0.75	0.43 [0.35, 0.53]	0.55	0.37	0.49 [0.41, 0.59]	0.28	0.27
40–50 mg/m²	1.88 [1.32, 2.69]			2.56 [1.52, 4.31]			0.38 [0.19, 0.76]			0.39 [0.26, 0.59]
60–80 mg/m²	1.83 [1.43, 2.32]			2.25 [1.61, 3.15]			0.39 [0.28, 0.55]			0.39 [0.29, 0.52]
Others	1.28 [0.64, 2.55]			2.68 [1.02, 7.01]			0.27 [0.11, 0.68]			0.22 [0.08, 0.66]
Table 3I. Subgroups analysis according to DDP dosage (Supplementary Figures S35–S50)
WHO	1.81 [1.58, 2.08]	0.85	0.87	2.17 [1.80, 2.62]	0.63	0.43	0.40 [0.32, 0.51]	0.66	0.91	0.45 [0.36, 0.55]	0.69	0.49
RECIST/NCI-CTCAE	1.85 [1.47, 2.31]			2.50 [1.90, 3.30]			0.36 [0.20, 0.66]			0.38 [0.22, 0.66]
Other	1.70 [0.82, 3.50]			3.64 [1.18, 11.23]			0.43 [0.34, 0.56]			0.46 [0.37, 0.56]

Note: AST: anticipated survival time; PT: primary treatment; RT: retreatment; Others: unclear or ungroupable; WHO: World Health Organization for solid tumor responses; OR: odds ratio; RECIST: Response Evaluation Criteria in Solid Tumors guideline; NCI-CTCAE: National Cancer Institute-Common Terminology Criteria for Adverse Events; UM: univariate meta-regression; and MM: multiple meta-regression.